6600.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 04:37):

Stats
Šios dienos apimtis	54 000.00
Vidutinė apimtis	4.45M
Rinkos kapitalizacija	11.30B
EPS	HKD0 ( 2023-08-17 )
Last Dividend	HKD0.390 ( 2023-06-02 )
Next Dividend	HKD0 ( N/A )
P/E	9.73
ATR14	HKD0.0120 (0.07%)

Tūris Koreliacija

Ilgas: 0.06 (neutral)

Trumpas: -0.22 (neutral)

Signal:(66.473) Neutral

SciClone Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

SciClone Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

0.56
( weak )

0.51
( weak )

0.00
( neutral )

-0.53
( weak negative )

SciClone Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	HKD3.16B
Bruto pelnas:	HKD2.36B (74.67 %)
EPS:	HKD1.830

FY	2023
Pajamos:	HKD3.16B
Bruto pelnas:	HKD2.36B (74.67 %)
EPS:	HKD1.830

FY	2022
Pajamos:	HKD2.75B
Bruto pelnas:	HKD2.07B (75.30 %)
EPS:	HKD1.270

FY	2021
Pajamos:	HKD2.52B
Bruto pelnas:	HKD1.93B (76.75 %)
EPS:	HKD1.420

Financial Reports:

No articles found.

SciClone Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.390 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

SciClone Pharmaceuticals, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.71 - Increase likely (54.12%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.350	2022-05-27
Last Dividend	HKD0.390	2023-06-02
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	HKD0.740	--
Avg. Dividend % Per Year	0.00%	--
Score	3.47	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.71
Div. Directional Score	9.85	--

Next Divdend (Est)
(2025-03-31)

HKD0.327 Estimate 3.00 %

Dividend Stability

0.24 Very Poor

Dividend Score

3.47

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8095.HK	Ex Dividend Junior	2023-10-17	Sporadic	0.00%
2009.HK	No Dividend Player	2023-05-18	Annually	0.00%
1084.HK	Ex Dividend Junior	2023-06-06	Semi-Annually	0.00%
0158.HK	Ex Dividend Junior	2023-06-15	Semi-Annually	0.00%
3698.HK	Ex Dividend Junior	2023-07-04	Annually	0.00%
1658.HK	Ex Dividend Junior	2023-07-05	Annually	0.00%
0697.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2217.HK	Ex Dividend Junior	2023-08-15	Annually	0.00%
1223.HK	No Dividend Player	2023-06-27	Sporadic	0.00%
0297.HK	Ex Dividend Junior	2023-06-23	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.356	1.500	2.89	4.33	[0 - 0.5]
returnOnAssetsTTM	0.280	1.200	0.651	0.782	[0 - 0.3]
returnOnEquityTTM	0.369	1.500	7.01	10.00	[0.1 - 1]
payoutRatioTTM	0.192	-1.000	8.08	-8.08	[0 - 1]
currentRatioTTM	4.94	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.16	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.59	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00494	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	35.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.894	2.00	9.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.893	2.00	9.55	10.00	[0 - 20]
debtEquityRatioTTM	0.00605	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.889	0.889	[0.2 - 0.8]
operatingProfitMarginTTM	0.382	1.000	4.36	4.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	29.32	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.789	0.800	8.07	6.46	[0.5 - 2]
Total Score				11.99

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.41	1.000	9.15	0	[1 - 100]
returnOnEquityTTM	0.369	2.50	8.08	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.893	2.00	9.70	10.00	[0 - 30]
dividendYielPercentageTTM	2.40	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.894	2.00	9.70	10.00	[0 - 30]
payoutRatioTTM	0.192	1.500	8.08	-8.08	[0 - 1]
pegRatioTTM	0.759	1.500	8.28	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.184	1.000	7.91	0	[0.1 - 0.5]
Total Score				7.71

SciClone Pharmaceuticals,

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.